Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.

Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, Goldsmith SJ, Ross JS, Bander NH.

J Clin Oncol. 2007 Feb 10;25(5):540-7.

PMID:
17290063
2.

Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen.

Nanus DM, Milowsky MI, Kostakoglu L, Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Bander NH.

J Urol. 2003 Dec;170(6 Pt 2):S84-8; discussion S88-9. Review.

PMID:
14610416
3.

Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody.

Vallabhajosula S, Nikolopoulou A, Jhanwar YS, Kaur G, Tagawa ST, Nanus DM, Bander NH, Goldsmith SJ.

Curr Radiopharm. 2016;9(1):44-53. Review.

PMID:
25771365
4.

Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen.

Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, Goldsmith SJ.

Semin Oncol. 2003 Oct;30(5):667-76. Review.

PMID:
14571414
5.

89Zr-Desferrioxamine B-J591 anti-prostate-specific membrane antigen monoclonal antibody.

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2010 Sep 12 [updated 2010 Nov 18].

6.

Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers.

Gong MC, Chang SS, Sadelain M, Bander NH, Heston WD.

Cancer Metastasis Rev. 1999;18(4):483-90. Review.

PMID:
10855791
7.

123I-Labeled (S)-2-(3-((S)-1-carboxy-5-(4-iodobenzylamino)pentyl)ureido)pentanedoic acid.

Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2009 Sep 29 [updated 2009 Nov 24].

8.

123I-Labeled (S)-2-(3-((S)-1-carboxy-5-(3-(4-iodophenyl) ureido)pentyl)ureido)pentanedoic acid.

Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2009 Sep 29 [updated 2009 Nov 24].

9.

Targeted therapies for prostate cancer against the prostate specific membrane antigen.

Elsässer-Beile U, Bühler P, Wolf P.

Curr Drug Targets. 2009 Feb;10(2):118-25. Review.

PMID:
19199907
10.

The utility of monoclonal antibodies in the imaging of prostate cancer.

Yao D, Trabulsi EJ, Kostakoglu L, Vallabhajosula S, Joyce MA, Nanus DM, Milowsky M, Liu H, Goldsmith SJ.

Semin Urol Oncol. 2002 Aug;20(3):211-8. Review.

PMID:
12215974
11.

Monoclonal antibodies and prostate-specific membrane antigen.

Chang SS.

Curr Opin Investig Drugs. 2004 Jun;5(6):611-5. Review.

PMID:
15242249
12.

Antibody-drug conjugates targeting prostate-specific membrane antigen.

Olson WC, Israel RJ.

Front Biosci (Landmark Ed). 2014 Jan 1;19:12-33. Review.

PMID:
24389170
13.

Prostate-specific membrane antigen-based imaging.

Osborne JR, Akhtar NH, Vallabhajosula S, Anand A, Deh K, Tagawa ST.

Urol Oncol. 2013 Feb;31(2):144-54. doi: 10.1016/j.urolonc.2012.04.016. Review.

14.

89Zr-Desferrioxamine B-7E11 anti-prostate-specific membrane antigen monoclonal antibody.

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2011 Nov 22 [updated 2012 Feb 23].

15.

A review: Integrin alphavbeta3-targeted molecular imaging and therapy in angiogenesis.

Lim EH, Danthi N, Bednarski M, Li KC.

Nanomedicine. 2005 Jun;1(2):110-4. Review. No abstract available.

PMID:
17292065
16.

The clinical and therapeutic uses of MDM2 and PSMA and their potential interaction in aggressive cancers.

Bradbury R, Jiang WG, Cui YX.

Biomark Med. 2015;9(12):1353-70. doi: 10.2217/bmm.15.94. Review.

17.

64Cu-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-anti-prostate-specific membrane antigen 3/A12 monoclonal antibody.

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2009 Aug 1 [updated 2009 Sep 16].

18.

Molecular targeting of angiogenesis.

Alessi P, Ebbinghaus C, Neri D.

Biochim Biophys Acta. 2004 Mar 4;1654(1):39-49. Review.

PMID:
14984766
19.

111In-Capromab pendetide .

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2005 Oct 5 [updated 2008 May 24].

20.

Radiopharmaceuticals for targeting the angiogenesis marker alpha(v)beta(3).

McQuade P, KnIght LC.

Q J Nucl Med. 2003 Sep;47(3):209-20. Review.

Supplemental Content

Support Center